Selpercatinib Demonstrates Promising Activity in RET Fusion-Positive Solid Tumors - OncLive
6/5/2022 12:00:00 AM2 years 10 months ago
by Tony Berberabe, MPH
by Tony Berberabe, MPH
Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.
Extended follow-up data from the LIBRETTO-001 (NCT03157128) demonstrated that selpercatinib (Retevmo) elicited durable responses in patients with RET fusion-positive solid tumors, including refractor… [+4737 chars]
full article...